HCA Healthcare, Inc.
$140.13B- Market cap
- $94.68B
- Debt
- +$46.49B
- Cash
- −$1.04B
Capital structure 67% equity / 33% debt · EV / Revenue 1.85x
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: HCA stock price at discount vs MRVL $426.78 current versus $2.13K implied using P/E multiple.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at MRVL's multiple
Implied fair value · at HCA's multiple
Snapshot Sep 11, 2026, 9:37 AM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth lag
Reported gross margin
Operating income + D&A
Multiple discount
Lower P/E
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
Nine period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Capital structure 67% equity / 33% debt · EV / Revenue 1.85x
Capital structure 98% equity / 2% debt · EV / Revenue 24.93x · EV proxy / EBITDA proxy 82.16x
MRVL carries the larger enterprise value at $204.30B against $140.13B; HCA trades on the lower EV / Revenue multiple (1.85x vs 24.93x).
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
HCA Healthcare, Inc. · implied price per share
Bear
$171.11
Base
$241.68
Bull
$336.89
MARVELL TECHNOLOGY, INC · implied price per share
Bear
$20.57
Base
$25.11
Bull
$31.24
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
LABCORP HOLDINGS INC.
HCA vs LH
WEST PHARMACEUTICAL SERVICES INC
HCA vs WST
BAXTER INTERNATIONAL INC
HCA vs BAX
MCKESSON CORP
HCA vs MCK
Cigna Group
HCA vs CI
UNITEDHEALTH GROUP INC
HCA vs UNH
INTEL CORP
HCA vs INTC
NVIDIA CORP
HCA vs NVDA
ADVANCED MICRO DEVICES INC
HCA vs AMD
Broadcom Inc.
HCA vs AVGO
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe HCA deserves only a modest healthcare-style multiple and not MRVL-like growth or margin assumptions, then avoid relying on MRVL-implied upside because the current price is already near the top of its historical band and MRVL comparison is structurally distorted by very different business models.
The valuation gap is exceptionally wide: HCA trades at $410.50 versus a P/E-implied value of $2,263.54, suggesting the market is already discounting a much lower multiple than MRVL comparison implies. The gap is largely driven by MRVL's much richer valuation multiples, which are not directly comparable to HCA's lower-growth healthcare profile.
Supporting Metrics